$0218: Phase II Study of Pegylated Liposomal Doxorubi-Cin (Pld) Plus Oxaliplatin (Oxa) for Resistant or Refractory Ovarian Cancer Patients$

0218: Phase II Study of Pegylated Liposomal Doxorubi-Cin (Pld) Plus Oxaliplatin (Oxa) for Resistant or Refractory Ovarian Cancer Patients

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of gynecological cancer 2006-10, Vol.16 (Suppl 3), p.662-662
Hauptverfasser:	Carlini, L., Villa, A., Busci, L., Trezzi, G., Gallo, A., Frigerio, L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Ovarian cancer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	662
container_issue	Suppl 3
container_start_page	662
container_title	International journal of gynecological cancer
container_volume	16
creator	Carlini, L. Villa, A. Busci, L. Trezzi, G. Gallo, A. Frigerio, L.
description
doi_str_mv	10.1136/ijgc-00009577-200610001-00218
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2552828093</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2552828093</sourcerecordid><originalsourceid>FETCH-LOGICAL-c823-7df7be28a20c74f66bc2be9d58d20cc036d69816c5a65b3a17c1782b77c23c463</originalsourceid><addsrcrecordid>eNo9kN1KxDAQhYsouK6-Q0AEvajmp01SwQupfwsLW3QvvAtpmq5duk1NWtk-gm9tuqvOzcw5nJmBLwguELxGiNCbar1SIfSVxIyFGEKKvEDewogfBBMU4zhEEeGHfoYRD3mC3o-DE-fW4xKGyST4HrO3IPuQToPZDLx1fTEAU4JMr4ZadroA86o1zmxkDR7M1tg-r8K0asBlVhdXIKt7BxZbWVetT4-2F1egNBa8ale5TjYd2InSStUZO4DFl7SVbEAqG6UtyPyabjp3GhyVsnb67LdPg-XT4zJ9CeeL51l6Pw8VxyRkRclyjbnEULGopDRXONdJEfPCOwoSWtCEI6piSeOcSMQUYhznjClMVETJNDjfn22t-ey168Ta9LbxHwWOY8wxhwnxqbt9SlnjnNWlaG21kXYQCIoRvhjhiz_44h--2MEnP5kxeIg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2552828093</pqid></control><display><type>article</type><title>0218: Phase II Study of Pegylated Liposomal Doxorubi-Cin (Pld) Plus Oxaliplatin (Oxa) for Resistant or Refractory Ovarian Cancer Patients</title><source>Access via Wiley Online Library</source><creator>Carlini, L. ; Villa, A. ; Busci, L. ; Trezzi, G. ; Gallo, A. ; Frigerio, L.</creator><creatorcontrib>Carlini, L. ; Villa, A. ; Busci, L. ; Trezzi, G. ; Gallo, A. ; Frigerio, L.</creatorcontrib><identifier>ISSN: 1048-891X</identifier><identifier>EISSN: 1525-1438</identifier><identifier>DOI: 10.1136/ijgc-00009577-200610001-00218</identifier><language>eng</language><publisher>Oxford: BMJ Publishing Group LTD</publisher><subject>Ovarian cancer</subject><ispartof>International journal of gynecological cancer, 2006-10, Vol.16 (Suppl 3), p.662-662</ispartof><rights>2006 2006 IGCS, International Journal of Gynecological Cancer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids></links><search><creatorcontrib>Carlini, L.</creatorcontrib><creatorcontrib>Villa, A.</creatorcontrib><creatorcontrib>Busci, L.</creatorcontrib><creatorcontrib>Trezzi, G.</creatorcontrib><creatorcontrib>Gallo, A.</creatorcontrib><creatorcontrib>Frigerio, L.</creatorcontrib><title>0218: Phase II Study of Pegylated Liposomal Doxorubi-Cin (Pld) Plus Oxaliplatin (Oxa) for Resistant or Refractory Ovarian Cancer Patients</title><title>International journal of gynecological cancer</title><subject>Ovarian cancer</subject><issn>1048-891X</issn><issn>1525-1438</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNo9kN1KxDAQhYsouK6-Q0AEvajmp01SwQupfwsLW3QvvAtpmq5duk1NWtk-gm9tuqvOzcw5nJmBLwguELxGiNCbar1SIfSVxIyFGEKKvEDewogfBBMU4zhEEeGHfoYRD3mC3o-DE-fW4xKGyST4HrO3IPuQToPZDLx1fTEAU4JMr4ZadroA86o1zmxkDR7M1tg-r8K0asBlVhdXIKt7BxZbWVetT4-2F1egNBa8ale5TjYd2InSStUZO4DFl7SVbEAqG6UtyPyabjp3GhyVsnb67LdPg-XT4zJ9CeeL51l6Pw8VxyRkRclyjbnEULGopDRXONdJEfPCOwoSWtCEI6piSeOcSMQUYhznjClMVETJNDjfn22t-ey168Ta9LbxHwWOY8wxhwnxqbt9SlnjnNWlaG21kXYQCIoRvhjhiz_44h--2MEnP5kxeIg</recordid><startdate>200610</startdate><enddate>200610</enddate><creator>Carlini, L.</creator><creator>Villa, A.</creator><creator>Busci, L.</creator><creator>Trezzi, G.</creator><creator>Gallo, A.</creator><creator>Frigerio, L.</creator><general>BMJ Publishing Group LTD</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope></search><sort><creationdate>200610</creationdate><title>0218: Phase II Study of Pegylated Liposomal Doxorubi-Cin (Pld) Plus Oxaliplatin (Oxa) for Resistant or Refractory Ovarian Cancer Patients</title><author>Carlini, L. ; Villa, A. ; Busci, L. ; Trezzi, G. ; Gallo, A. ; Frigerio, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c823-7df7be28a20c74f66bc2be9d58d20cc036d69816c5a65b3a17c1782b77c23c463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Ovarian cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carlini, L.</creatorcontrib><creatorcontrib>Villa, A.</creatorcontrib><creatorcontrib>Busci, L.</creatorcontrib><creatorcontrib>Trezzi, G.</creatorcontrib><creatorcontrib>Gallo, A.</creatorcontrib><creatorcontrib>Frigerio, L.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>International journal of gynecological cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carlini, L.</au><au>Villa, A.</au><au>Busci, L.</au><au>Trezzi, G.</au><au>Gallo, A.</au><au>Frigerio, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>0218: Phase II Study of Pegylated Liposomal Doxorubi-Cin (Pld) Plus Oxaliplatin (Oxa) for Resistant or Refractory Ovarian Cancer Patients</atitle><jtitle>International journal of gynecological cancer</jtitle><date>2006-10</date><risdate>2006</risdate><volume>16</volume><issue>Suppl 3</issue><spage>662</spage><epage>662</epage><pages>662-662</pages><issn>1048-891X</issn><eissn>1525-1438</eissn><cop>Oxford</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ijgc-00009577-200610001-00218</doi><tpages>1</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 1048-891X
ispartof	International journal of gynecological cancer, 2006-10, Vol.16 (Suppl 3), p.662-662
issn	1048-891X 1525-1438
language	eng
recordid	cdi_proquest_journals_2552828093
source	Access via Wiley Online Library
subjects	Ovarian cancer
title	0218: Phase II Study of Pegylated Liposomal Doxorubi-Cin (Pld) Plus Oxaliplatin (Oxa) for Resistant or Refractory Ovarian Cancer Patients
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-09T23%3A38%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=0218:%20Phase%20II%20Study%20of%20Pegylated%20Liposomal%20Doxorubi-Cin%20(Pld)%20Plus%20Oxaliplatin%20(Oxa)%20for%20Resistant%20or%20Refractory%20Ovarian%20Cancer%20Patients&rft.jtitle=International%20journal%20of%20gynecological%20cancer&rft.au=Carlini,%20L.&rft.date=2006-10&rft.volume=16&rft.issue=Suppl%203&rft.spage=662&rft.epage=662&rft.pages=662-662&rft.issn=1048-891X&rft.eissn=1525-1438&rft_id=info:doi/10.1136/ijgc-00009577-200610001-00218&rft_dat=%3Cproquest_cross%3E2552828093%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2552828093&rft_id=info:pmid/&rfr_iscdi=true